Wedmont Private Capital Grows Position in Eli Lilly and Company $LLY

Key Points

• Wedmont Private Capital increased its Eli Lilly stake by 8.4% in the second quarter, bringing its holdings to 16,064 shares valued at approximately $19.1 million. Institutional investors collectively own 82.53% of LLY.
• Eli Lilly reported strong quarterly results, with earnings per share of $8.38 and revenue of $22.97 billion, up 47.7% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $1,292.18.
• Lilly’s growth outlook is supported by Mounjaro’s expanded cardiovascular indication and a growing neuroscience pipeline, but competition from Novo Nordisk, patent-expiration risks and recent sector selling remain concerns.

Wedmont Private Capital raised its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 8.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,064 shares of the company's stock after acquiring an additional 1,242 shares during the period. Wedmont Private Capital's holdings in Eli Lilly and Company were worth $19,094,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Integrity Financial Corp WA lifted its position in shares of Eli Lilly and Company by 1.3% during the second quarter. Integrity Financial Corp WA now owns 639 shares of the company's stock valued at $767,000 after purchasing an additional 8 shares in the last quarter. Willner & Heller LLC grew its position in Eli Lilly and Company by 1.0% in the 2nd quarter. Willner & Heller LLC now owns 917 shares of the company's stock worth $1,100,000 after purchasing an additional 9 shares in the last quarter. Aspiring Ventures LLC grew its position in Eli Lilly and Company by 3.7% in the 2nd quarter. Aspiring Ventures LLC now owns 255 shares of the company's stock worth $306,000 after purchasing an additional 9 shares in the last quarter. Wealthspan Partners LLC increased its stake in Eli Lilly and Company by 0.4% in the 2nd quarter. Wealthspan Partners LLC now owns 2,120 shares of the company's stock valued at $2,543,000 after buying an additional 9 shares during the last quarter. Finally, Navigoe LLC increased its stake in Eli Lilly and Company by 8.7% in the 2nd quarter. Navigoe LLC now owns 113 shares of the company's stock valued at $135,000 after buying an additional 9 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA’s approval of Mounjaro to reduce the risk of heart attack or stroke in certain adults with type 2 diabetes could expand the drug’s addressable market and support Lilly’s next phase of growth. Could Mounjaro’s New Heart Benefit Unlock the Next Growth Phase for Lilly?
• Positive Sentiment: Analyst sentiment remains favorable, with Lilly’s average brokerage recommendation signaling optimism about its growth outlook, although such ratings can be biased toward positive recommendations. Wall Street Bulls Look Optimistic About Lilly
• Positive Sentiment: Lilly is expanding its neuroscience pipeline through internal development and acquisitions, offering potential long-term growth beyond its diabetes and obesity franchise. Lilly Builds Neuroscience into a New Long-Term Growth Driver
• Positive Sentiment: Recent acquisitions could strengthen Lilly’s pipeline and diversify its future revenue base, though investors are assessing whether the deals will justify their cost. Eli Lilly Has Been on an Acquisition Spree
• Neutral Sentiment: Lilly’s strong GLP-1 growth remains the central investment thesis, but investors are also focused on increasing competition and the eventual impact of patent expirations for Mounjaro, Zepbound and related products. Lilly’s Acquisition Strategy and GLP-1 Competition
• Negative Sentiment: Novartis’ failure in a closely watched cardiovascular trial for an Lp(a)-lowering cholesterol drug pressured the broader drug class and raised concerns about clinical and commercial risk for companies pursuing similar opportunities, including Lilly. Eli Lilly Stock Falls on Novartis Cholesterol Drug Setback
• Negative Sentiment: The stock faced broader healthcare-sector selling and a technical breakdown, which intensified the pullback despite Lilly’s favorable long-term fundamentals. Why Is Eli Lilly Stock Falling Tuesday?
• Negative Sentiment: Novo Nordisk’s positive pediatric semaglutide study highlights continued competitive progress in obesity treatment, potentially increasing pressure on Lilly’s GLP-1 franchise. Novo Nordisk’s Semaglutide Meets Goal in Pediatric Obesity Study

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. The Goldman Sachs Group restated a "buy" rating and issued a $1,283.00 target price on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Berenberg Bank increased their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a "hold" rating in a research report on Monday, June 22nd. Bank of America lifted their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a "buy" rating in a report on Friday, July 10th. UBS Group set a $1,376.00 price objective on Eli Lilly and Company in a research report on Friday, August 7th. Finally, Truist Financial upped their price objective on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a "buy" rating in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $1,292.18.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares of the company's stock, valued at $14,131,250. The trade was a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Trading Down 2.2%

Shares of LLY stock opened at $1,123.60 on Wednesday. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The firm has a market cap of $1.06 trillion, a P/E ratio of 37.70, a PEG ratio of 1.42 and a beta of 0.50. The company has a 50 day moving average of $1,188.61 and a 200-day moving average of $1,071.38. Eli Lilly and Company has a 12-month low of $712.05 and a 12-month high of $1,292.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. During the same period in the prior year, the company earned $6.31 earnings per share. Eli Lilly and Company's revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 36.35 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company's dividend payout ratio is presently 23.22%.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company's products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.